Summary A retrospective analysis was performed of 18 patients with primary malignant germ cell tumours of the mediastinum treated with platinum-based chemotherapy between 1977 and 1990. All seven patients with pure seminoma were treated initially with chemotherapy and four of these patients received additional mediastinal radiotherapy. Only one patient relapsed; his initial therapy had included radiotherapy and single-agent carboplatin and he was successfully salvaged with combination chemotherapy. With a follow-up of 11 to 117 months (median 41 months) all seven patients with seminoma remain alive and disease free giving an overall survival of 100%. Eleven patients had malignant non seminoma; following chemotherapy eight of these had elective surgical resection of residual mediastinal masses. Complete remission was achieved in nine (82%) patients, however, one of these patients died from bleomycin pneumonitis. With a follow-up of 12 to 113 months (median 55 months) eight of 11 (73%) patients with malignant mediastinal teratoma remain alive and disease free.
Although rare, primary malignant germ cell tumours of the mediastinum are a clinically important group of tumours which account for 5 to 13% of all malignant mediastinal tumours (Oberman & Libke, 1964; Cox, 1975; Raghaven, 1991) . It is estimated that 1 to 4% of all primary malignant germ cell tumours arise from an extragonadal site (Collins & Pugh, 1964) of which the anterior mediastinum is the second most common. Despite having a spectrum of histology similar to primary gonadal tumours it has been reported that they have a worse prognosis compared to metastatic germ cell tumours of gonadal origin (Kuzur et al., 1982; Feun et al., 1980; Toner et al., 1991; Vugrin et al., 1981) . This certainly appears to be true for mediastinal teratoma, however, most reports now show that good results can be obtained from using platinum based chemotherapy for primary mediastinal seminoma (Israel et al., 1985) . The current prognosis of mediastinal teratoma has been difficult to assess because many reported series extend back over a long time period. We have restricted this analysis to the era of platinum based chemotherapy and have assessed all patients referred to the Testicular Tumour Unit at the Royal Marsden Hospital with primary malignant germ cell tumours of the mediastinum between 1977 and 1989 . Results on several of these patients have been reported elsewhere (Horwich et al., 1986; Kay et al., 1987) .
Patients details and methods
The study was a retrospective review of all case notes of patients with the diagnosis of primary malignant mediastinal germ cell tumour who had received platinum based chemotherapy at the RMH between 1977 and 1989 . The criteria for inclusion were that patients had to present with a mass in the anterior mediastinum, have histology or marker evidence of a germ cell tumour; and have normal testes on initial and subsequent examinations. The distinction from occult testicular primary cancer was based on the location of the mass within the anterior mediastinum, since this is an extremely uncommon metastatic site from overt testicular primaries. Patients who had received previous chemotherapy were excluded. Four patients with seminoma and six with nonseminoma were reported previously (Horwich et al., 1986) , but the follow-up data has been extended.
Patient characteristics
The patients were all male and had a median age ) (five patients) followed by mediastinal radiotherapy to a total midplane dose of 30 Gy in 15 fractions over 3 weeks. Other chemotherapy protocols used for seminoma were BEP (Peck-ham et al., 1983) (two patients) and PVB (Einhorn & Donohue, 1977) (one patient). The chemotherapy protocols used for teratoma were PVB (two patients), BEP (one patient), BEVIP (Peckham et al., 1988 ) (two patients) and a combination of these protocols (two patients). More recently an intensive schedule CBOP-BEP, based on the BOP-BEP protocol developed for use in poor prognosis metastatic malignant teratoma, has been used. The modification was the incorporation of carboplatin with cisplatin to increase platinum dose intensity in the first phase of treatment (Table III) . Carboplatin was added to weeks 2 and 4 of the standard BOP-BEP schedule to a dose designed to achieve a serum concentration x time of 2 mg, ml-' min (Calvert et al., 1989) Substantially elevated tumour markers (Table II) were present in ten patients with teratoma at the time of referral; the one patient with no significant elevation of markers had extensive surgical resection of his mediastinal tumour prior to referral. Normalisation of the markers had occurred in four patients following chemotherapy and in four patients following both chemotherapy and surgery. Marked reduction of the marker levels was seen in the two patients obtaining a partial response but they never fell to normal. A modest elevation of BetaHCG (Table I) was measured in two patients with seminoma which returned to normal following chemotherapy.
It has been suggested that there is an association between mediastinal germ cell tumour and haematological neoplasia (Nichols et al., 1990b) (Table IV) an overall survival in excess of 80% can be expected with the use of chemotherapy with or without radiotherapy (Horwich & Peckham, 1986; McLeod et al., 1988; Kiffer & Sandeman, 1989; Logothetis et al., 1985; Giaccone et al., 1991; Kersh et al., 1987) . Based on this study and a recent report on the treatment for metastatic seminoma it appears that single agent carboplatin may be an appropriate first line treatment for patients with primary mediastinal seminoma, though excellent results are found with cisplatinbased combination chemotherapy, and for smaller tumours radiotherapy alone is effective (Table IV) . More intensive regimens may provide a good chance of successful salvage should relapse occur after carboplatin chemotherapy (Horwich, 1990) . As reported in this and other studies (Schultz et al., 1989) , a proportion of patients will continue to have a persistent soft tissue mass evident on CXR or CT scanning after attaining a complete remission. Whether the addition of mediastinal radiotherapy would improve the relapse free survival is not established.
All the patients with teratoma in this study had very bulky mediastinal disease and all but one had high serum tumour markers, factors which are known to predict for a poor prognosis (Mead et al., 1992) . It is possible that the prognosis for mediastinal teratoma is not independent of the prognostic factors identified for malignant testicular germ cell tumours.
The results of treatment for patients with malignant teratoma of the mediastinum remain less satisfactory. Studies reported since 1985 show a range of overall survival from 21% to 63% (Horwich & Peckham, 1986; McLeod et al., 1988; Kiffer & Sandeman, 1989; Logothetis et al., 1986; Giaccone et al., 1991; Kersh et al., 1987; Parker et al., 1986; Nichols et al., 1990a; Toner et al., 1991) (Table V) . Previous reports were even more gloomy (Fuen et al., 1980; Israel et al., 1985) . In these studies many different types of chemotherapy were used; a proportion of patients in some studies did not receive platinum-based chemotherapy, some patients received radiotherapy only and there was not a consistent policy of surgical resection for residual masses. The overall survival of 73% in our study is encouraging and suggests that experience with platinum based chemotherapy, in conjunction with surgical resection of residual mediastinal masses, may be leading to an improved outlook for these patients.
It is recommended that chemotherapy for mediastinal seminoma be based on carboplatin or cisplatinum possibly as single agents. Because patients with non-seminomatous germ cell tumours of the mediastinum have an adverse prognosis continued use of more intensive cisplatinum based combination chemotherapy is advised.
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